Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantSC
Surveyor Capital
Activity from announced rounds
All recorded activity
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $586M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in all activityAdcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedSoley Therapeutics
Uses cells as sensors to uncover first-in-class medicines
$200MSeries C
Role not disclosed